Berenberg Bank Reaffirms “Buy” Rating for Life Science REIT (LON:LABS)

Berenberg Bank reaffirmed their buy rating on shares of Life Science REIT (LON:LABS) in a research report released on Thursday morning, Marketbeat.com reports. The firm currently has a GBX 57 ($0.76) price objective on the stock.

Several other analysts have also commented on the company. Jefferies Financial Group dropped their price objective on Life Science REIT from GBX 45 ($0.60) to GBX 36 ($0.48) and set a hold rating on the stock in a report on Friday, August 30th. Shore Capital reissued a buy rating on shares of Life Science REIT in a report on Thursday, September 26th.

Life Science REIT Stock Down 2.5 %

LON:LABS opened at GBX 39 ($0.52) on Thursday. Life Science REIT has a 52 week low of GBX 31.30 ($0.42) and a 52 week high of GBX 74.20 ($0.99). The stock’s 50-day moving average price is GBX 34.15 and its 200-day moving average price is GBX 35.86. The stock has a market capitalization of £136.50 million, a PE ratio of -650.00 and a beta of 0.08.

Life Science REIT Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Thursday, October 31st. Shareholders of record on Thursday, October 3rd will be paid a dividend of GBX 1 ($0.01) per share. The ex-dividend date is Thursday, October 3rd. This represents a yield of 3.11%. Life Science REIT’s dividend payout ratio (DPR) is currently -3,333.33%.